ProCE Banner Series

Bridging Discoveries to Practice—CCO’s Conference to Clinic Highlights From the 2024 ASH Annual Meeting

Join us for live, interactive webinars to hear experts discuss some of the most important abstracts presented during the 2024 ASH annual meeting and answer audience questions on the data. Full details on the available topics are provided below.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for healthcare professionals, physicians, nurses, physician associates and pharmacists who care for patients with malignant or nonmalignant hematologic disorders.

All Events

Bridging Discoveries to Practice—CCO’s Conference to Clinic Highlights From the 2024 ASH Annual Meeting

Upcoming Events

January

18

2025

8:00 AM - 1:20 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Topics

  • Hematologic malignancies
  • Leukemias, lymphomas
  • Multiple myeloma
  • Myelodysplastic syndromes
  • Myeloproliferative neoplasms
  • Nonmalignant hematologic disorders 

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ understanding of how to optimally apply recent practice-changing findings from approved and investigational agents to the care of patients with malignant or nonmalignant hematologic disorders.

Target Audience
This program is intended for healthcare professionals, physicians, nurses, physician associates and pharmacists who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Appraise how new trial findings might advance the treatment of patients with malignant or nonmalignant hematologic disorders in the future

  • Counsel patients with malignant or nonmalignant hematologic disorders on ongoing clinical trial opportunities to ensure inclusive enrollment and equitable care

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Multiple Myeloma: 1.0
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN): 0.75
Leukemias: 1.0
Lymphomas: 1.0
Nonmalignant Hematology: 0.75

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.5 contact hours.

Multiple Myeloma: 1.0
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN): 0.75
Leukemias: 1.0
Lymphomas: 1.0
Nonmalignant Hematology: 0.75

Continuing Pharmacy Education

CCO designates this continuing education activity for 4.5 contact hours (0.45 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each topic 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Multiple Myeloma: 1.0
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN): 0.75
Leukemias: 1.0
Lymphomas: 1.0
Nonmalignant Hematology: 0.75

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Multiple Myeloma: 1.0
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN): 0.75
Leukemias: 1.0
Lymphomas: 1.0
Nonmalignant Hematology: 0.75

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.